Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Steven Paul Hanlon

Hans Iding

Andrew William Thomas

Paul Spurr

Pius Waldmeier

Ernst Kupfer

Roland Jakob-Roetne

Bernd Buettelmann

Matthew C Lucas

Ping Wang

Beat Wirz

Uwe Bornscheuer

Stefan Hildbrand

Roumen Nikolaev Radinov

Stephen Deems Gabriel

Lianhe Shu

Pascal Dott

Stephan Doswald

Martin Steffen Weiss

Ioannis Pavlidis

The present invention relates to a mutant transaminase with increased transaminase activity relative to the wild-type transaminase, a fusion protein comprising the transaminase, a polynucleotide coding for the transaminase, a host cell comprising the polynucleotide, mutant transaminase and/or fusion protein, a method of producing an amine with the mutant transaminase or fusion protein and the use of the mutant transaminase or fusion protein for the production of an amine.

Mutant transaminases as well as methods and uses relating thereto

The present invention relates to a process for the preparation of a compound of formula (I) wherein Rand Rare as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.

Process for the preparation of isoxazolyl-methoxy nicotinic acids

The present invention is concerned with novel hydroxy-methyl isoxazole derivatives of formula I wherein R, Rand Rare as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A &#x3b1;5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as pharmaceuticals.

Substituted isoxazoles

The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and Ris hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.

Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide

The invention relates to a scalable biocatalytic process for the preparation of S-1,1,1-trifluoro-2-propanol with a enantiomeric excess of &#x3e;99% by asymmetric microbial reduction of 1,1,1-trifluoroacetone with Baker's yeast.

Asymmetric reduction of 1,1,1-trifluoroacetone

Growing community of inventors

Bottmingen, Switzerland

Steven Paul Hanlon